Effects of 1α,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Wang, Wei Lin W ^a   Chatterjee, Namita ^a   Chittur, Sridar V ^a   Welsh, JoEllen ^a   Tenniswood, Martin P ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM ION; CELL NUCLEUS RECEPTOR; MESSENGER RNA; MICRORNA; TESTOSTERONE; ANDROGEN; DIHYDROXY VITAMIN D3; DIHYDROXY-VITAMIN D3; DRUG DERIVATIVE; VITAMIN; VITAMIN D;

ARTICLE; CALCIUM HOMEOSTASIS; CANCER GROWTH; CANCER INVASION; CELL CYCLE PROGRESSION; CELL DEATH; CELL MOTILITY; CELL PROLIFERATION; CELL STRAIN LNCAP; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; LIPOGENESIS; MALE; MICROARRAY ANALYSIS; MOLECULAR MECHANICS; PHENOTYPE; PROMOTER REGION; PROSTATE CANCER; RNA DEGRADATION; SECOND MESSENGER; SIGNAL TRANSDUCTION; STEADY STATE; TREATMENT RESPONSE; TUMOR GROWTH; UPREGULATION; VITAMIN D RESPONSIVE ELEMENT; CELL CYCLE; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HOMEOSTASIS; METABOLISM; MOLECULAR GENETICS; PATHOPHYSIOLOGY; PROSTATE TUMOR; REPRODUCIBILITY; TUMOR CELL LINE;

ANDROGENS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEOSTASIS; HUMANS; MALE; MICRORNAS; MOLECULAR SEQUENCE ANNOTATION; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; TESTOSTERONE; VITAMIN D; VITAMINS;

EID: 79955979276     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-58     Document Type: Article

References (68)

1. Surveillance Epidemiology and End Results Web. , http://seer.cancer.gov
2. Lamont KR, Tindall DJ. Androgen regulation of gene expression. Adv Cancer Res 2010, 107:137-162.
3. Vis AN, Schroder FH. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU Int 2009, 104:438-448. 10.1111/j.1464-410X.2009.08695.x, 19558559.
4. Vis AN, Schroder FH. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase. BJU Int 2009, 104:1191-1197. 10.1111/j.1464-410X.2009.08743.x, 19624596.
5. Giovannucci E. Expanding roles of vitamin D. J Clin Endocrinol Metab 2009, 94:418-420. 10.1210/jc.2008-2695, 19193916.
6. Thorne J, Campbell MJ. The vitamin D receptor in cancer. Proc Nutr Soc 2008, 67:115-127. 10.1017/S0029665108006964, 18412986.
7. Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer prevention: global perspective. Ann Epidemiol 2009, 19:468-483. 10.1016/j.annepidem.2009.03.021, 19523595.
8. Schwartz GG, Skinner HG. Vitamin D status and cancer: new insights. Curr Opin Clin Nutr Metab Care 2007, 10:6-11.
9. Tseng M, Breslow RA, DeVellis RF, Ziegler RG. Dietary patterns and prostate cancer risk in the National Health and Nutrition Examination Survey Epidemiological Follow-up Study cohort. Cancer Epidemiol Biomarkers Prev 2004, 13:71-77. 10.1158/1055-9965.EPI-03-0076, 14744736.
10. Barnett CM, Nielson CM, Shannon J, Chan JM, Shikany JM, Bauer DC, et al. Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control 2010, 21:1297-1303. 10.1007/s10552-010-9557-y, 2903686, 20383574.
11. Park SY, Cooney RV, Wilkens LR, Murphy SP, Henderson BE, Kolonel LN. Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort. Eur J Cancer 2010, 46:932-936. 10.1016/j.ejca.2009.12.030, 2834847, 20064705.
12. Rhee HV, Coebergh JW, Vries ED. Sunlight, vitamin D and the prevention of cancer: a systematic review of epidemiological studies. Eur J Cancer Prev 2009,
13. Yin L, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk. Cancer Epidemiol 2009, 33:435-445. 10.1016/j.canep.2009.10.014, 19939760.
14. Alagbala AA, Moser MT, Johnson CS, Trump DL, Foster BA. Characterization of Vitamin D insensitive prostate cancer cells. J Steroid Biochem Mol Biol 2007, 103:712-716. 10.1016/j.jsbmb.2006.12.008, 1892312, 17280828.
15. Banach-Petrosky W, Ouyang X, Gao H, Nader K, Ji Y, Suh N, et al. Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice. Clin Cancer Res 2006, 12:5895-5901. 10.1158/1078-0432.CCR-06-1039, 17020998.
16. Mordan-McCombs S, Brown T, Wang WL, Gaupel AC, Welsh J, Tenniswood M. Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status. J Steroid Biochem Mol Biol 2010, 121:368-371. 10.1016/j.jsbmb.2010.03.062, 20347977.
17. Murthy S, Agoulnik IU, Weigel NL. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate 2005, 64:362-372. 10.1002/pros.20251, 15754350.
18. Oades GM, Dredge K, Kirby RS, Colston KW. Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int 2002, 90:607-616. 10.1046/j.1464-410X.2002.02964.x, 12230626.
19. Saito T, Okamoto R, Haritunians T, O'Kelly J, Uskokovic M, Maehr H, et al. Novel Gemini vitamin D(3) analogs have potent antitumor activity. J Steroid Biochem Mol Biol 2008, 112:151-156. 2648831, 18938245.
20. Washington MN, Kim JS, Weigel NL. 1alpha,25-dihydroxyvitamin D(3) inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G(1) arrest. Prostate 2010,
21. Bao BY, Yao J, Lee YF. 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 2006, 27:1883-1893. 10.1093/carcin/bgl041, 16624828.
22. Ben Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ. 1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther 2007, 6:1433-1439. 10.1158/1535-7163.MCT-06-0677, 17431122.
23. Jiang F, Bao J, Li P, Nicosia SV, Bai W. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. J Biol Chem 2004, 279:53213-53221. 10.1074/jbc.M410395200, 15485861.
24. Kizildag S, Ates H, Kizildag S. Treatment of K562 cells with 1,25-dihydroxyvitamin D(3) induces distinct alterations in the expression of apoptosis-related genes BCL2, BAX, BCL(XL), and p21. Ann Hematol 2009,
25. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 2000, 87:214-220.
26. Campbell MJ, Koeffler HP. Toward therapeutic intervention of cancer by vitamin D compounds. J Natl Cancer Inst 1997, 89:182-185. 10.1093/jnci/89.3.182, 9016994.
27. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995, 1:997-1003.
28. Zhuang SH, Burnstein KL. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998, 139:1197-1207. 10.1210/en.139.3.1197, 9492054.
29. Weigel NL. Interactions between vitamin D and androgen receptor signaling in prostate cancer cells. Nutr Rev 2007, 65:S116-S117. 10.1301/nr.2007.aug.S116-S117, 17867385.
30. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008, 68:6162-6170. 10.1158/0008-5472.CAN-08-0144, 2597340, 18676839.
31. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007, 67:6130-6135. 10.1158/0008-5472.CAN-07-0533, 17616669.
32. Li T, Li D, Sha J, Sun P, Huang Y. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 2009, 383:280-285. 10.1016/j.bbrc.2009.03.077, 19302977.
33. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 2009, 69:7165-7169. 10.1158/0008-5472.CAN-09-1448, 2861586, 19738047.
34. Sun T, Yang M, Kantoff P, Lee GS. Role of microRNA-221/-222 in cancer development and progression. Cell Cycle 2009, 8:2315-2316. 10.4161/cc.8.15.9221, 19625765.
35. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA 2007, 104:19983-19988. 10.1073/pnas.0706641104, 2148409, 18056640.
36. Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, White RW. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate 2011, 71:538-549. 10.1002/pros.21270, 20886540.
37. Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 2008, 14:417-424. 10.1261/rna.874808, 2248249, 18174313.
38. Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA, Cohen MB. MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther 2008, 7:1288-1296. 10.4161/cbt.7.8.6284, 18497571.
39. Thorne JL, Maguire O, Doig CL, Battaglia S, Fehr L, Sucheston LE, et al. Epigenetic control of a VDR-governed feed-forward loop that regulates p21(waf1/cip1) expression and function in non-malignant prostate cells. Nucleic Acids Res 2011, 39:2045-2056. 10.1093/nar/gkq875, 3064804, 21088000.
40. Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM, Feldman D. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 2004, 59:243-251. 10.1002/pros.20006, 15042599.
41. Peehl DM, Shinghal R, Nonn L, Seto E, Krishnan AV, Brooks JD, et al. Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol 2004, 92:131-141. 10.1016/j.jsbmb.2004.07.003, 15555907.
42. Wang TT, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, Nagai Y, et al. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol 2005, 19:2685-2695. 10.1210/me.2005-0106, 16002434.
43. Mohri T, Nakajima M, Takagi S, Komagata S, Yokoi T. MicroRNA regulates human vitamin D receptor. Int J Cancer 2009, 125:1328-1333. 10.1002/ijc.24459, 19437538.
44. Wang WL, McHenry P, Jeffrey R, Schweitzer D, Helquist P, Tenniswood M. Effects of Iejimalide B, a marine macrolide, on growth and apoptosis in prostate cancer cell lines. J Cell Biochem 2008, 105:998-1007. 10.1002/jcb.21898, 18773415.
45. Colston KW, Hansen CM. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 2002, 9:45-59. 10.1677/erc.0.0090045, 11914182.
46. Harris DM, Go VL. Vitamin D and colon carcinogenesis. J Nutr 2004, 134:3463S-3471S.
47. Welsh J, Wietzke JA, Zinser GM, Smyczek S, Romu S, Tribble E, et al. Impact of the Vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer. J Steroid Biochem Mol Biol 2002, 83:85-92. 10.1016/S0960-0760(02)00277-7, 12650704.
48. Zhang X, Nicosia SV, Bai W. Vitamin D receptor is a novel drug target for ovarian cancer treatment. Curr Cancer Drug Targets 2006, 6:229-244. 10.2174/156800906776842939, 16712459.
49. Khan MT, Wagner L, Yule DI, Bhanumathy C, Joseph SK. Akt kinase phosphorylation of inositol 1,4,5-trisphosphate receptors. J Biol Chem 2006, 281:3731-3737.
50. Al Ansary D, Bogeski I, Disteldorf BM, Becherer U, Niemeyer BA. ATP modulates Ca2+ uptake by TRPV6 and is counteracted by isoform-specific phosphorylation. FASEB J 2010, 24:425-435. 10.1096/fj.09-141481, 19805577.
51. Tombal B, Denmeade SR, Gillis JM, Isaacs JT. A supramicromolar elevation of intracellular free calcium ([Ca(2+)](i)) is consistently required to induce the execution phase of apoptosis. Cell Death Differ 2002, 9:561-573. 10.1038/sj.cdd.4400999, 11973614.
52. Szabadkai G, Duchen MR. Mitochondria: the hub of cellular Ca2+ signaling. Physiology (Bethesda) 2008, 23:84-94.
53. Sonkoly E, Wei T, Pavez LE, Suzuki H, Kato M, Torma H, et al. Protein kinase C-dependent upregulation of miR-203 induces the differentiation of human keratinocytes. J Invest Dermatol 2010, 130:124-134. 10.1038/jid.2009.294, 19759552.
54. Vanden Abeele F, Skryma R, Shuba Y, Van Coppenolle F, Slomianny C, Roudbaraki M, et al. Bcl-2-dependent modulation of Ca(2+) homeostasis and store-operated channels in prostate cancer cells. Cancer Cell 2002, 1:169-179. 10.1016/S1535-6108(02)00034-X, 12086875.
55. Flourakis M, Prevarskaya N. Insights into Ca2+ homeostasis of advanced prostate cancer cells. Biochim Biophys Acta 2009, 1793:1105-1109. 10.1016/j.bbamcr.2009.01.009, 19339216.
56. Foradori CD, Weiser MJ, Handa RJ. Non-genomic actions of androgens. Front Neuroendocrinol 2008, 29:169-181. 10.1016/j.yfrne.2007.10.005, 2386261, 18093638.
57. Nakagawa K, Tsugawa N, Okamoto T, Kishi T, Ono T, Kubodera N, et al. Rapid control of transmembrane calcium influx by 1alpha,25-dihydroxyvitamin D3 and its analogues in rat osteoblast-like cells. Biol Pharm Bull 1999, 22:1058-1063.
58. Steinsapir J, Socci R, Reinach P. Effects of androgen on intracellular calcium of LNCaP cells. Biochem Biophys Res Commun 1991, 179:90-96. 10.1016/0006-291X(91)91338-D, 1883394.
59. Cheng HT, Chen JY, Huang YC, Chang HC, Hung WC. Functional role of VDR in the activation of p27Kip1 by the VDR/Sp1 complex. J Cell Biochem 2006, 98:1450-1456. 10.1002/jcb.20780, 16518840.
60. Huang YC, Hung WC. 1,25-dihydroxyvitamin D3 transcriptionally represses p45Skp2 expression via the Sp1 sites in human prostate cancer cells. J Cell Physiol 2006, 209:363-369. 10.1002/jcp.20741, 16883603.
61. McGaffin KR, Chrysogelos SA. Identification and characterization of a response element in the EGFR promoter that mediates transcriptional repression by 1,25-dihydroxyvitamin D3 in breast cancer cells. J Mol Endocrinol 2005, 35:117-133. 10.1677/jme.1.01813, 16087726.
62. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 2009, 69:7165-7169. 10.1158/0008-5472.CAN-09-1448, 2861586, 19738047.
63. Xiong J, Du Q, Liang Z. Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene 2010, 29:4980-4988. 10.1038/onc.2010.241, 20562918.
64. Boominathan L. The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex. PLoS One 2010, 5:e10615. 10.1371/journal.pone.0010615, 2868896, 20485546.
65. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 2008, 283:1026-1033.
66. Trump DL, Chadha MK, Sunga AY, Fakih MG, Ashraf U, Silliman CG, et al. Vitamin D deficiency and insufficiency among patients with prostate cancer. BJU Int 2009, 104:909-914. 10.1111/j.1464-410X.2009.08531.x, 2889216, 19426195.
67. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
68. Huang D, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.